204 related articles for article (PubMed ID: 33107983)
1. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
Borthakur G; Martinelli G; Raffoux E; Chevallier P; Chromik J; Lithio A; Smith CL; Yuen E; Oakley GJ; Benhadji KA; DeAngelo DJ
Cancer; 2021 Feb; 127(3):372-380. PubMed ID: 33107983
[TBL] [Abstract][Full Text] [Related]
2. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
Even C; Lassen U; Merchan J; Le Tourneau C; Soria JC; Ferte C; Ricci F; Diener JT; Yuen E; Smith C; Oakley GJ; Benhadji KA; Massard C
Invest New Drugs; 2020 Apr; 38(2):402-409. PubMed ID: 30953269
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.
Doi T; Tajimi M; Mori J; Asou H; Inoue K; Benhadji KA; Naito Y
Invest New Drugs; 2021 Apr; 39(2):469-476. PubMed ID: 32939607
[TBL] [Abstract][Full Text] [Related]
4. A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Azaro A; Massard C; Tap WD; Cassier PA; Merchan J; Italiano A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
Invest New Drugs; 2021 Aug; 39(4):1089-1098. PubMed ID: 33686452
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.
Azaro A; Baldini C; Rodon J; Soria JC; Yuen E; Lithio A; Oakley G; Benhadji KA; Massard C
Invest New Drugs; 2021 Feb; 39(1):193-201. PubMed ID: 32915419
[TBL] [Abstract][Full Text] [Related]
6. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
7. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
Massard C; Azaro A; Soria JC; Lassen U; Le Tourneau C; Sarker D; Smith C; Ohnmacht U; Oakley G; Patel BKR; Yuen ESM; Benhadji KA; Rodon J
Ann Oncol; 2018 Sep; 29(9):1911-1917. PubMed ID: 30060061
[TBL] [Abstract][Full Text] [Related]
8. A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
Massard C; Cassier PA; Azaro A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
Cancer Chemother Pharmacol; 2022 Oct; 90(4):335-344. PubMed ID: 36030462
[TBL] [Abstract][Full Text] [Related]
9. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
11. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
13. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
Morita K; Jain N; Kantarjian H; Takahashi K; Fang H; Konopleva M; El Hussein S; Wang F; Short NJ; Maiti A; Sasaki K; Garcia-Manero G; Konoplev S; Ravandi F; Khoury JD; Jabbour E
Am J Hematol; 2021 May; 96(5):589-598. PubMed ID: 33639000
[TBL] [Abstract][Full Text] [Related]
14. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
Suzuki K; Sunami K; Matsumoto M; Maki A; Shimada F; Suzuki K; Shimizu K
Acta Haematol; 2021; 144(3):264-274. PubMed ID: 33279887
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010.
Gao YJ; Pan C; Tang JY; Lu FJ; Chen J; Xue HL; Zhai XW; Li J; Ye QD; Zhou M; Wang HS; Miao H; Qian XW; Xu Z; Meng JH
Pediatr Blood Cancer; 2014 Apr; 61(4):659-63. PubMed ID: 24243691
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
Thomas DA; Kantarjian HM; Stock W; Heffner LT; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Pierce S; Lu B; Deitcher SR; O'Brien S
Cancer; 2009 Dec; 115(23):5490-8. PubMed ID: 19708032
[TBL] [Abstract][Full Text] [Related]
17. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
[TBL] [Abstract][Full Text] [Related]
18. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects.
Yuen E; Posada M; Smith C; Thorn K; Greenwood D; Burgess M; A Benhadji K; Ortega D; Chinchen L; Suico J
Cancer Chemother Pharmacol; 2019 Mar; 83(3):483-492. PubMed ID: 30539232
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
